(19 Dec 18) Novartis Australia has announced the TGA approval of Kymriah® (tisagenlecleucel), for the treatment of two types of aggressive cancers. This one-time treatment is called “CAR-T” cellular therapy, and it is manufactured individually for each patient, using the patient’s own immune system cells.
Kymriah® is approved in Australia for the treatment of relapsed or refractory patients with paediatric B-cell acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL).
We congratulate Novartis on this significant achievement which will bring a life changing treatments to patients in need.